Andrew Zloza, MD, PhD

Highly focused (obsessed?) and gifted (maybe just obsessed?) scientist studying "bugs as drugs" for cancer immunotherapy. Views (including this one) are my own!

[Andrew Zloza, MD, PhD @AndrewZloza]

Congrats to our (@amarzo67) student @prestondaniels_ for completing this PhD studies with the publication of this manuscript describing another way that the intratumoral #Influenza #Vaccine reduces breast cancer growth. https://t.co/tejkwXVI8R #mdpiijms via @IJMS_MDPI @RushDOIM

[Andrew Zloza, MD, PhD @AndrewZloza]

Very honored to be starting a new faculty position in the Department of Surgery at the University of Texas Medical Branch (UTMB) in Galveston! Thanks to all those who made this transition possible! @utmbhealth @JochenReiser @KlimbergV @UTMBSurgery

[Jochen Reiser MD PhD @JochenReiser]

This team science paper offers a mechanism for diabetic kidney disease. The D2D3 form of uPAR acts as an immunotoxin and may cause diabetes and kidney disease | Science Translational Medicine
⁦@salimhayek⁩
⁦@KeZhu3304⁩
⁦@ASNKidney⁩ https://t.co/cabppEkY6v

[Journal for ImmunoTherapy of Cancer @jitcancer]

Meet the Author: Dr. Andrew Zloza (@AndrewZloza), an Associate Professor from @RushDOIM, @RushUniversity, @RushMedical, & senior author of “Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer,” out in #JITC! 1/6

[Jochen Reiser MD PhD @JochenReiser]

It’s a wrap ! 11 years ⁦⁦@RushMedical⁩ !
I have fond memories and hopefully have created lasting impact ⁦@RushDOIM⁩.
It has been a privilege to lead our outstanding Department of Medicine.
Thank you !

[Vineet Gupta 🧬🧫 @gupta__vineet]

Huge congratulations @JochenReiser on establishing and leaving a legacy of a thriving Dept of Medicine @ Rush and beginning an even more ambitious new journey @ utmb. 👏👏👏

[Vineet Gupta 🧬🧫 @gupta__vineet]

Congrats @salimhayek @JochenReiser and team on a fabulous new study further linking extrarenal innate immune activation with glomerular injury and pathology. Very cool mechanism! 👏👏👏

[Jochen Reiser MD PhD @JochenReiser]

Cracking down on cancers ! Great work by @AndrewZlozaand colleagues.
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory c… https://t.co/RjdyTRs7XM

[Journal for ImmunoTherapy of Cancer @jitcancer]

Here is a deeper look at recent #JITC publication: “Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer” 1/5

[Andrew Zloza, MD, PhD @AndrewZloza]

Much thanks to the organizers of the @harvardmed @BrighamWomens “Skin Inflammation in Human Health and Disease 2023 International Conference” & especially to Rachael Clark for the invite! It was a great in-person experience, awesome audience, & well worth the COVID-delayed wait.

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer https://t.co/T3sUjDM7Tp @sachinrjhawar @Praveen_IO @HowardK39084949 @AndrewZloza

[Andrew Zloza, MD, PhD @AndrewZloza]

Much thanks to @NorthwesternMed @NUFeinbergMed Department of Microbiology-Immunology and Andrew Cogswell for hosting me last week! Great audience during my seminar with superb questions and wonderful faculty meetings!

[RUSH Internal Medicine @RushDOIM]

Congratulations, Dr. Reiser!! @JochenReiser @RushMedical

[Andrew Zloza, MD, PhD @AndrewZloza]

Amazing news! So well-deserved for @JochenReiser at @RushMedical and such a great new leader for @utmbhealth. Best wishes from everyone! @ASNKidney @dgfn_ev @the_asci https://t.co/T0i3yEEYyW

[Jochen Reiser MD PhD @JochenReiser]

This pretty much sums it all up.

[Society for Immunotherapy of Cancer @sitcancer]

The latest edition of the #JITC Reading List is out. Social Media Editor Dr. Praveen K. Bommareddy (@Praveen_IO) selects articles that add value to what readers find in the Journal for ImmunoTherapy of Cancer. Enjoy articles from the #immunotherapy field https://t.co/YP2u2blIRp

[Andrew Zloza, MD, PhD @AndrewZloza]

@DelgoffeLab @BReinfeld @jitcancer @JimAllisonPhD @PamSharmaMDPhD @PatrickHwuMD Thanks @DelgoffeLab - I almost missed this! – & yes, Coley had the right idea – now we are trying to implement “bugs as drugs” as cancer IT (https://t.co/961AUiuJuV) – with the flu season approaching, maybe tumors could benefit from an i.t. flu shot!? (https://t.co/JhvllK0xaf)

[Jason M Schenkel @JMSchenkel]

I am thrilled to announce that the Schenkel Lab will open it’s doors on Sept 15th @MDAndersonNews @MDA_UTHGrad. This is the culmination of many years of blood, sweat, and tears. I am over the moon excited to join such an incredible group of people focused on #endcancer. 1/

[Jason M Schenkel @JMSchenkel]

I am forever indebted to those who have taken me under their wing. @AndrewZloza for introducing me to Immunology, and sending me down an entirely different life path. Without your guidance, who knows where I would have ended up. Maybe back in New Jersey. 3/

[Rush Department of Surgery @RushSurgery]

Having previously shown that an intratumoural injection of a commercially available seasonal influenza vaccination can turn cold tumors into hot tumors, @KajalGupta04 has now looked into the potential antitumor effects of the inactivated SARS-CoV-2 virus: https://t.co/yenI8jMRfO